ITCSX
Price
$29.35
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
RAMHX
Price
$36.42
Change
-$0.05 (-0.14%)
Updated
Nov 13 closing price
Ad is loading...

ITCSX vs RAMHX

Header iconITCSX vs RAMHX Comparison
Open Charts ITCSX vs RAMHXBanner chart's image
VY® T. Rowe Price Capital Apprec S
Price$29.35
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
American Funds American Balanced R2E
Price$36.42
Change-$0.05 (-0.14%)
VolumeN/A
CapitalizationN/A
ITCSX vs RAMHX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ITCSX vs. RAMHX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ITCSX is a Buy and RAMHX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RAMHX has more cash in the bank: 240B vs. ITCSX (6.74B). RAMHX pays higher dividends than ITCSX: RAMHX (1.84) vs ITCSX (1.72). ITCSX was incepted earlier than RAMHX: ITCSX (36 years) vs RAMHX (10 years). ITCSX has a lower initial minimum investment than RAMHX: ITCSX (0) vs RAMHX (250). RAMHX annual gain was more profitable for investors over the last year : 24.19 vs. ITCSX (21.42). RAMHX return over 5 years is better than : 35.28 vs. ITCSX (9.06).
ITCSXRAMHXITCSX / RAMHX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence36 years10 years-
Gain YTD13.02915.28985%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets6.74B240B3%
Annual Yield % from dividends1.721.8494%
Returns for 1 year21.4224.1989%
Returns for 3 years-6.8510.96-63%
Returns for 5 years9.0635.2826%
Returns for 10 years17.2149.4135%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZYME17.400.07
+0.40%
Zymeworks
HAL30.190.06
+0.20%
Halliburton Company
REFI15.64-0.01
-0.06%
Chicago Atlantic Real Estate Finance
WTM1901.49-8.46
-0.44%
White Mountains Insurance Group Ltd
MRKR3.72-0.07
-1.85%
Marker Therapeutics